BioCentury | Jun 7, 2019
Targets & Mechanisms
Following PARP, ATR axis next in line to expand synthetic lethal drug class
...ATRN-119 and ATRN-212 are in preclinical testing. 2. Chk1 inhibitors. Sierra Oncology Inc. (NASDAQ:SRRA) has SRA737...
...targets in the ATR pathway. Sierra presented two Phase I/II studies of its Chk1 inhibitor SRA737...
...three out of 10 patients had partial responses. The most common adverse events for Sierra's SRA737...
...targets in the ATR pathway. Sierra presented two Phase I/II studies of its Chk1 inhibitor SRA737...
...three out of 10 patients had partial responses. The most common adverse events for Sierra's SRA737...
